These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36038111)

  • 41. MMDAE-HGSOC: A novel method for high-grade serous ovarian cancer molecular subtypes classification based on multi-modal deep autoencoder.
    Wang HQ; Li HL; Han JL; Feng ZP; Deng HX; Han X
    Comput Biol Chem; 2023 Aug; 105():107906. PubMed ID: 37336028
    [TBL] [Abstract][Full Text] [Related]  

  • 42. OvaPrint-A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer.
    Buckley DN; Lewinger JP; Gooden G; Spillman M; Neuman M; Guo XM; Tew BY; Miller H; Khetan VU; Shulman LP; Roman L; Salhia B
    Clin Cancer Res; 2023 Dec; 29(24):5196-5206. PubMed ID: 37812492
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evolving population-based statistics for rare epithelial ovarian cancers.
    Matsuo K; Machida H; Matsuzaki S; Grubbs BH; Klar M; Roman LD; Sood AK; Gershenson DM; Wright JD
    Gynecol Oncol; 2020 Apr; 157(1):3-11. PubMed ID: 31954534
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
    Takaya H; Nakai H; Takamatsu S; Mandai M; Matsumura N
    Sci Rep; 2020 Feb; 10(1):2757. PubMed ID: 32066851
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SOCS7/HuR/FOXM1 signaling axis inhibited high-grade serous ovarian carcinoma progression.
    Du Y; Xu X; Lv S; Liu H; Sun H; Wu J
    J Exp Clin Cancer Res; 2022 May; 41(1):185. PubMed ID: 35624501
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Many Microenvironments of Ovarian Cancer.
    Micek HM; Visetsouk MR; Fleszar AJ; Kreeger PK
    Adv Exp Med Biol; 2020; 1296():199-213. PubMed ID: 34185294
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing.
    Lee JY; Yoon JK; Kim B; Kim S; Kim MA; Lim H; Bang D; Song YS
    BMC Cancer; 2015 Feb; 15():85. PubMed ID: 25881093
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A systematic review and meta-analysis of hormone receptor expression in low-grade serous ovarian carcinoma.
    Voutsadakis IA
    Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():172-178. PubMed ID: 33246201
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Functional analysis and validation of oncodrive gene AP3S1 in ovarian cancer through filtering of mutation data from whole-exome sequencing.
    Kong D; Wu Y; Liu Q; Huang C; Wang T; Huang Z; Gao Y; Li Y; Guo H
    Eur J Med Res; 2024 Apr; 29(1):231. PubMed ID: 38609993
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Global characterization of extrachromosomal circular DNAs in advanced high grade serous ovarian cancer.
    Cen Y; Fang Y; Ren Y; Hong S; Lu W; Xu J
    Cell Death Dis; 2022 Apr; 13(4):342. PubMed ID: 35418185
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma.
    Zhou H; Liu Q; Shi X; Liu Y; Cao D; Yang J
    J Ovarian Res; 2020 Apr; 13(1):38. PubMed ID: 32295618
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TRAF4 promotes the malignant progression of high-grade serous ovarian cancer by activating YAP pathway.
    Luo X; Cao J; Zhang C; Huang H; Liu J
    Biochem Biophys Res Commun; 2022 Oct; 627():68-75. PubMed ID: 36029535
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DNA methylation-based profiling reveals distinct clusters with survival heterogeneity in high-grade serous ovarian cancer.
    Wang J; Li J; Chen R; Yue H; Li W; Wu B; Bai Y; Zhu G; Lu X
    Clin Epigenetics; 2021 Oct; 13(1):190. PubMed ID: 34645493
    [TBL] [Abstract][Full Text] [Related]  

  • 54. LGR4 maintains HGSOC cell epithelial phenotype and stem-like traits.
    Wang Z; Yin P; Sun Y; Na L; Gao J; Wang W; Zhao C
    Gynecol Oncol; 2020 Dec; 159(3):839-849. PubMed ID: 32980127
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Integrated molecular profiling of patient-derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities.
    Lupia M; Melocchi V; Bizzaro F; Lo Riso P; Dama E; Baronio M; Ranghiero A; Barberis M; Bernard L; Bertalot G; Giavazzi R; Testa G; Bianchi F; Cavallaro U
    Int J Cancer; 2022 Jul; 151(2):240-254. PubMed ID: 35218560
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epithelial/mesenchymal heterogeneity of high-grade serous ovarian carcinoma samples correlates with miRNA let-7 levels and predicts tumor growth and metastasis.
    Chirshev E; Hojo N; Bertucci A; Sanderman L; Nguyen A; Wang H; Suzuki T; Brito E; Martinez SR; Castañón C; Mirshahidi S; Vazquez ME; Wat P; Oberg KC; Ioffe YJ; Unternaehrer JJ
    Mol Oncol; 2020 Nov; 14(11):2796-2813. PubMed ID: 32652647
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
    Morra F; Merolla F; Damia G; Ricci F; Varricchio S; Ilardi G; Arenare L; Califano D; Napolitano V; Fruscio R; Melillo RM; Palazzo L; Celetti A
    J Exp Clin Cancer Res; 2022 Aug; 41(1):245. PubMed ID: 35964058
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clonal Evolution of
    Garziera M; Cecchin E; Giorda G; Sorio R; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Ecca F; Canzonieri V; Toffoli G
    Cells; 2019 Oct; 8(10):. PubMed ID: 31581548
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
    Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
    J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.